Toll-like receptor 4 (TLR4) plays a critical role in the innate immune system and is involved in the pathogenesis of multiple diseases. Here, we report the antagonistic and ratized antibody, 52-1H4 e2 (e2), which completely inhibited lipopolysaccharide-induced interleukin-6 secretion in vitro. The average serum drug concentration was above 10 μg/mL for 28 days in rats injected with e2. The novel anti-rat TLR4/myeloid differentiation factor 2 antibody, e2, may be a useful tool for investigating the role of TLR4 in rat disease models.
Get full access to this article
View all access options for this article.
References
1.
UematsuS, and AkiraS: Toll-like receptors and type I Interferons. J Biol Chem, 2007; 282:15319–15324.
2.
ParkBS, SongDH, KimHM, ChoiBS, LeeH, and LeeJO: The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 2009; 458:1191–1195.
3.
YangY, LvJ, JiangS, MaZ, WangD, HuW, DengC, FanC, DiS, SunY, and YiW: The emerging role of toll-like receptor 4 in myocardial inflammation. Cell Death Dis, 2016; 7:e2234.
4.
LepeniesJ, EardleyKS, KienitzT, HewisonM, IhlT, StewartPM, CockwellP, and QuinklerM: Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-β 1 in patients with chronic kidney disease. Nephron - Clin Pract, 2011; 119:97–104.
5.
ChenJ, JohnR, RichardsonJA, SheltonJM, ZhouXJ, WangY, WuQQ, HartonoJR, WinterbergPD, and LuCY: Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int, 2011; 79:288–299.
6.
SpillerS, ElsonG, FerstlR, DreherS, MuellerT, FreudenbergM, DaubeufB, WagnerH, and KirschningCJ: TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med, 2008; 205:1747–1754.
7.
TakashimaK, MatsunagaN, YoshimatsuM, HazekiK, KaishoT, UekataM, HazekiO, AkiraS, IizawaY, and IiM: Analysis of binding site for the novel small-molecul TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol, 2009; 157:1250–1262.
8.
ImaiK, and TakaokaA: Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer, 2006; 9:714–727.
9.
LinJH: Pharmacokinetics of biotech drugs: Peptides, proteins and monoclonal antibodies. Curr Drug Metab, 2009; 7:661–691.
10.
OoC, and KalbagSS: Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: A new wave of revolution in drug development. Expert Rev Clin Pharmacol, 2016; 9:747–749.
11.
ZhangZ, LiW, SunD, ZhaoL, ZhangR, WangY, ZhouX, WangH, and CaoF: Toll-like receptor 4 signaling in dysfunction of cardiac microvascular endothelial cells under hypoxia/reoxygenation. Inflamm Res, 2011; 60:37–45.
12.
ZhouS, WangG, and ZhangW: Effect of TLR4/MyD88 signaling pathway on sepsis-associated acute respiratory distress syndrome in rats, via regulation of macrophage activation and inflammatory response. Exp Ther med, 2018; 15:3376–3384.
13.
JonesST, and BendigMM: Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Bio/Technology, 1991; 9:579.
14.
Kabat EA, Wu TT, Foeller C, Perry HM, and Gottesman KS: Sequences of Proteins of Immunological Interest, Diane Pub Co, Darby, PA, 1992.
15.
ChothiaC, and LeskAM: Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol, 1987; 196:901–917.
16.
AlmagroJC, and FranssonJ: Humanization of antibodies. Front Biosci, 2008; 13:1619–1633.
17.
IsaacsJD, and WaldmannH: Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther Immunol, 1994; 1:303–312.
18.
DurrantLG, RobinsRA, MarksmanRA, GarnettMC, OgunmuyiwaY, and BaldwinRW: Abrogation of antibody responses in rats to murine monoclonal antibody 791T/36 by treatment with daunomycin-cis-aconityl-791T/36 conjugates. Cancer Immunol Immunother, 1989; 28:37–42.
19.
Gómez-MantillaJD, TrocónizIF, Parra-GuillénZ, and GarridoMJ: Review on modeling anti-antibody responses to monoclonal antibodies. J Pharmacokinet Pharmacodyn, 2014; 41:523–536.
20.
DegryseB, BonaldiT, ScaffidiP, MüllerS, ResnatiM, SanvitoF, ArrigoniG, and BianchiME: The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol, 2001; 152:1197–1206.
21.
HreggvidsdottirHS, ÖstbergT, WähämaaH, SchierbeckH, AvebergerA-C, KlevenvallL, PalmbladK, OttossonL, AnderssonU, and HarrisHE: The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol, 2009; 86:655–662.
